The etiology of Parkinson's disease (PD) is complex and not fully understood, most probably because of the multiplicity of factors involved. Inflammatory and abnormal immune responses have been hypothesized to play a crucial role in PD. Not only in the brain, but also peripherally, inflammation is believed to contribute to the onset and progression of the neurodegenerative process seen in PD. Furthermore, increased inflammatory responses have been described both in the brain and peripheral blood of PD subjects. Although PD is considered a motor disorder, nonmotor symptoms are extremely frequent and disabling. Cognitive impairment and mood alterations are such symptoms that deserve increased attention since on the one hand they can appear even before typical motor disturbances are recognized, and on the other hand they are associated with high morbidity and mortality. A growing body of evidence suggests the existence of a link between inflammatory-immune responses and the occurrence of depression and cognitive impairment in PD patients. However, not all data are equally conclusive and are sometimes even conflicting. The aim of this brief review is to give an overview of the possible role that inflammation and immunomodulation may play in PD together with their putative impact on mood and cognitive alterations. What clearly emerges from this work is the fact that studies performed until now lack standardized and comparable methods to analyze both clinical and biological parameters. It is thus difficult to conclusively link mood and cognitive changes to underlying pathological mechanisms. Additional studies in this direction are warranted to convincingly establish or refute any causative relation.

Keywords:
Parkinson’s disease, Inflammation, Immune system, Cognition, Depression
1.
de Lau LM, Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535.
2.
Bekris LM, Mata IF, Zabetian CP: The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010;23:228-242.
3.
Samii A, Nutt JG, Ransom BR: Parkinson's disease. Lancet 2004;363:1783-1793.
4.
Collins LM, Toulouse A, Connor TJ, Nolan YM: Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 2012;62:2154-2168.
5.
Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O: Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One 2012;7:e47387.
6.
Katsarou Z, Bostantjopoulou S, Hatzizisi O, Giza E, Soler-Cardona A, Kyriazis G: Immune factors or depression? Fatigue correlates in Parkinson's disease. Rev Neurol 2007;45:725-728.
7.
Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnekov A: The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010;51:474-479.
8.
Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ: Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011;69:655-663.
9.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
10.
Martí MJ, Tolosa E: Parkinson disease: New guidelines for diagnosis of Parkinson disease. Nat Rev Neurol 2013;9:190-191.
11.
Jain S, Goldstein DS: What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy. Neurobiol Dis 2012;46:505-507.
12.
Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M: Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis 2012;2012:198316.
13.
Parkinson J: An essay on the shaking palsy: 1817. J Neuropsychiatry Clin Neurosci 2002;14:223-236.
14.
McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
15.
Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM: A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005;128:2665-2674.
16.
Tansey MG, McCoy MK, Frank-Cannon TC: Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1-25.
17.
Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B: Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol 2007;64:836-840.
18.
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H: Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010;42:781-785.
19.
Gagne JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010;74:995-1002.
20.
Scalzo P, Kümmer A, Cardoso F, Teixeira AL: Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010;468:56-58.
21.
Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stepien A: Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008;441:158-162.
22.
Scalzo P, Kümmer A, Cardoso F, Teixeira AL: Increased serum levels of soluble tumor necrosis factor-α receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009;216:122-125.
23.
Stypuła G, Kunert-Radek J, Stepień H, Zylińska K, Pawlikowski M: Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation 1996;3:131-134.
24.
Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D: Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 2009;119:332-337.
25.
Mihara T, Nakashima M, Kuroiwa A, Akitake Y, Ono K, Hosokawa M, Yamada T, Takahashi M: Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Parkinsonism Relat Disord 2008;14:46-51.
26.
Scalzo P, de Miranda AS, Guerra Amaral DC, de Carvalho Vilela M, Cardoso F, Teixeira AL: Serum levels of chemokines in Parkinson's disease. Neuroimmunomodulation 2011;18:240-244.
27.
Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M: Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009;23:55-63.
28.
Klüter H, Vieregge P, Stolze H, Kirchner H: Defective production of interleukin-2 in patients with idiopathic Parkinson's disease. J Neurol Sci 1995;133:134-139.
29.
Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A: Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008;167:90-95.
30.
Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, Ambrosio S, Buendia E: Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 2001;113:146-152.
31.
Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T: Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005;11:493-498.
32.
Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey KM, Torres-Russotto DR, Meza JL, Santamaria PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, Gendelman HE: CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol 2012;7:927-938.
33.
Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, Ward C, Halliday GM: Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol 2012;252:95-99.
34.
Calopa M, Bas J, Callén A, Mestre M: Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis 2010;38:1-7.
35.
Niwa F, Kuriyama N, Nakagawa M, Imanishi J: Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int 2012;12:102-107.
36.
Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y: Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 2001;58:1580-1583.
37.
Prigione A, Isaias IU, Galbussera A, Brighina L, Begni B, Andreoni S, Pezzoli G, Antonini A, Ferrarese C: Increased oxidative stress in lymphocytes from untreated Parkinson's disease patients. Parkinsonism Relat Disord 2009;15:327-328.
38.
Kummer A, Teixeira AL: Neuropsychiatry of Parkinson's disease. Arq Neuropsiquiatr 2009;67:930-939.
39.
Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA: Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669-677.
40.
Gallagher DA, Schrag A: Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis 2012;46:581-589.
41.
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF: A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.
42.
Kummer A, Harsányi E, Dias FM, Cardoso F, Caramelli P, Teixeira AL: Depression impairs executive functioning in Parkinson disease patients with low educational level. Cogn Behav Neurol 2009;22:167-172.
43.
Pagonabarraga J, Kulisevsky J: Cognitive impairment and dementia in Parkinson's disease. Neurobiol Dis 2012;46:590-596.
44.
Capuron L, Miller AH: Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130:226-238.
45.
Dufek M, Hamanová M, Lokaj J, Goldemund D, Rektorová I, Michálková Z, Sheardová K, Rektor I: Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 2009;15:318-320.
46.
Hassin-Baer S, Cohen OS, Vakil E, Molshazki N, Sela BA, Nitsan Z, Chapman J, Tanne D: Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease? J Neural Transm 2011;118:539-543.
47.
Kummer A, Teixeira AL: Depressive disorders in Parkinson's disease may be due to a shared immune-mediated neurodegenerative process. Med Hypotheses 2008;70:201-202.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.